Related Experiment Video
Updated: Mar 7, 2026
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota;
Christopher Staley1, Matthew J Hamilton1, Byron P Vaughn2
1BioTechnology Institute, University of Minnesota, St Paul, MN, USA.
Objectives:
Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile infection (R-CDI) that cannot be cured with antibiotics alone. In addition, FMT is being investigated for a variety of indications where restoration or restructuring of the gut microbial community is hypothesized to be beneficial. We sought to develop a stable, freeze-dried encapsulated preparation of standardized fecal microbiota that can be used for FMT with ease and convenience in clinical practice and research.
Methods:
We systematically developed a lyophilization protocol that preserved the viability of bacteria across the taxonomic spectrum found in fecal microbiota and yielded physicochemical properties that enabled consistent encapsulation. We also treated a cohort of R-CDI patients with a range of doses of encapsulated microbiota and analyzed the associated changes in the fecal microbiome of the recipients.
Results:
The optimized lyophilized preparation satisfied all our preset goals for physicochemical properties, encapsulation ease, stability at different temperatures, and microbiota viability in vitro and in vivo (germ-free mice). The capsule treatment was administered to 49 patients. Overall, 43/49 (88%) of patients achieved a clinical success, defined as no recurrence of CDI over 2 months. Analysis of the fecal microbiome demonstrated near normalization of the fecal microbial community by 1 month following FMT treatment. The simplest protocol using the lowest dose (2.1-2.5 × 1011 bacteria in 2-3 capsules) without any colon purgative performed equally well in terms of clinical outcomes and microbiota engraftment.
Conclusions:
A single administration of encapsulated, freeze-dried fecal microbiota from a healthy donor was highly successful in treating antibiotic-refractory R-CDI syndrome.
Insights
Freeze-dried encapsulated fecal microbiota offers a convenient and effective treatment for recurrent Clostridium difficile infection (R-CDI). This novel preparation achieved high clinical success rates and restored gut microbiome balance in patients unresponsive to antibiotics.
Area of Science:
- Microbiology
- Gastroenterology
- Microbiome research
Background:
- Recurrent Clostridium difficile infection (R-CDI) poses a significant challenge, often refractory to antibiotic therapies.
- Fecal microbiota transplantation (FMT) shows promise for restoring gut microbial balance.
- Standardized, stable preparations are needed for widespread clinical adoption of FMT.
Purpose of the Study:
- To develop a stable, freeze-dried, encapsulated fecal microbiota preparation for convenient FMT.
- To assess the efficacy and microbiome impact of this preparation in R-CDI patients.
Main Methods:
- A systematic lyophilization protocol was optimized to preserve bacterial viability and enable consistent encapsulation.
- Encapsulated microbiota was administered to 49 R-CDI patients at varying doses.
- Fecal microbiome analysis was performed to evaluate engraftment and community structure changes.
Main Results:
- The optimized preparation demonstrated excellent stability, viability, and encapsulation properties.
- 88% (43/49) of patients achieved clinical success, defined as no CDI recurrence within 2 months.
- Microbiome analysis revealed near-normalization of the gut microbial community one month post-FMT.
- A simplified protocol with a lower dose (2-3 capsules) was as effective as higher doses.
Conclusions:
- A single dose of encapsulated, freeze-dried fecal microbiota is highly effective for antibiotic-refractory R-CDI.
- This standardized preparation simplifies FMT administration and shows significant clinical benefit.
- The study highlights the potential of encapsulated FMT for managing R-CDI and other microbiome-related disorders.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS